• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Kidney international supplements. >T-cell co-stimulatory blockade in kidney transplantation: back to the bench
【24h】

T-cell co-stimulatory blockade in kidney transplantation: back to the bench

机译：肾移植中的T细胞共刺激性阻断

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

It is believed that blocking positive T-cell co-stimulatory pathways should lead to long-term graft acceptance. Despite the exciting initial achievements in experimental animal models, targeting co-stimulatory pathways has shown to be much more complex in the clinic. In addition to multiple binding partners, some co-stimulatory interactions have been found to be inhibitory in nature, whereas others were demonstrated to be important in the development of regulatory T cells. Moreover, memory T cells have been shown to be resistant to co-stimulation blockade. Herein we focus on the B7: CD28 pathway and describe the evolution of targeting this pathway with cytotoxic T-lymphocyte antigen4- Ig from bench to clinic. We also attempt to address possible causes for the unexpected high rejection rate observed in the phase III clinical trials with belatacept, using experimental data obtained from basic science research.
机译：相信阻断阳性T细胞共刺激途径应导致长期移植物接受。尽管在实验动物模型中取得了令人兴奋的初步成就，但在临床中，靶向共刺激途径已被证明更为复杂。除了多个结合配偶体，还发现某些共刺激相互作用本质上具有抑制作用，而其他相互作用在调节性T细胞的发育中也很重要。此外，记忆T细胞已显示出对共刺激阻断有抵抗力。在本文中，我们重点关注B7：CD28途径，并描述了从长凳到临床使用具有细胞毒性T淋巴细胞抗原4- Ig靶向该途径的演变。我们还尝试使用从基础科学研究中获得的实验数据来解决在贝拉西普的III期临床试验中观察到的意外高排斥率的可能原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号